Homologation de Santé Canada : OLUMIANT® devient la deuxième traitement autorisé de l’alopécie areata sévère au Canada
De 17 à 22 % des patients recevant OLUMIANT à 2 mg/jour et de 32 à 35 % des patients recevant OLUMIANT à 4 mg/jour
OLUMIANT® Receives Health Canada Approval, Becoming the Second Approved Treatment for Severe Alopecia Areata in Canada
Eli Lilly Canada Inc. announced today that OLUMIANT (baricitinib) received regulatory approval for its severe alopecia areata indication via Notice of Compliance (NOC) from Health Canada.
Navigate With Confidence
Navigate with Confidence: Mental Health Resources Resources Music & Wellbeing Handbook